VIDA Diagnostics Secures $11M Series C Back to HomeCORALVILLE, IA, VIDA Diagnostics, ("VIDA"), the leader in AI-powered lung imaging analysis, today announced an $11M initial close of its Series C financing.

The investment was led by First Analysis Corporation with initial equity participation from Blue Heron Capital and UnityPoint Health Ventures.

VIDA can now accelerate LungPrint's market access, further connecting its benefits to the many millions of patients with lung disease."

About UnityPoint Health VenturesFounded in 2019, UnityPoint Health Ventures makes direct investments in ideas and partners that provide an easier, more personal experience for patients and providers.

In addition to strategic investing, UnityPoint Health Ventures provides dedicated resources to accelerate portfolio company traction within UnityPoint Health and beyond. | To read full story, visit https://startuparound.com/read/1584050415.5760539/VIDA-Diagnostics-Secures-$11M-Series-C?ref=audio_experience